Use of selective serotonin reuptake inhibitors in the treatment of burning mouth syndrome.

Abstract

BACKGROUND:

Patients with burning mouth syndrome (BMS) are frequently treated with antidepressants. Selective serotonin reuptake inhibitors (SSRIs) are increasingly used. Nonetheless, few studies have examined the effects of SSRIs in BMS.

OBJECTIVE:

We performed a retrospective study to confirm the need for a prospective study on this topic in the future.

PATIENTS AND METHODS:

51 patients suffering from primary BMS were included in this study.

RESULTS:

The frequency of side effects due to SSRIs was low, with mainly digestive side effects. Treatment with SSRIs was more efficient in patients reporting a psychogenic origin for their symptoms. Antidepressants were more frequently stopped when patients did not declare such an origin.

CONCLUSIONS:

SSRIs appear to be effective and well tolerated. Declaring a psychogenic component may be considered as a potentiating or predictive factor for the efficacy of treatment with SSRIs. These results should be confirmed by a prospective randomised study.

• Authors: Camille Fleuret, Guy Le Toux, Jehanne Morvan, Felipe Ferreira, Myriam Chastaing, Gérard Guillet, Laurent Misery
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 228 Issue 2 Pg. 172-6 ( 2014) ISSN: 1421-9832 [Electronic] Switzerland
• PMID: 24557331 (Publication Type: Comparative Study, Journal Article, Validation Study)
• Copyright: © 2014 S. Karger AG, Basel.

Chemical References

• Antidepressive Agents, Tricyclic
• Serotonin Uptake Inhibitors

Topics

• Aged
• Antidepressive Agents, Tricyclic (therapeutic use)
• Burning Mouth Syndrome (diagnosis, drug therapy)
• Female
• Humans
• Male
• Middle Aged
• Reproducibility of Results
• Retrospective Studies
• Selective Serotonin Reuptake Inhibitors (therapeutic use)
• Treatment Outcome